Measuring the Impact of Secondary Progressive Multiple Sclerosis (Spms) in the Ascend Trial: Equating the Msis-29, MSWS-12, Abilhand-56 and Sf-36

Value in Health - United Kingdom
doi 10.1016/j.jval.2015.09.2688
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Prm197 - Responder Definition of the Multiple Sclerosis Impact Scale (Msis)-29 V2 Among Patients With Secondary Progressive Multiple Sclerosis

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Prolonged-Release Fampridine Treatment Improved Subject-Reported Impact of Multiple Sclerosis: Item-Level Analysis of the MSIS-29

Journal of the Neurological Sciences
Neurology
2016English

The SF-36 in Multiple Sclerosis: Why Basic Assumptions Must Be Tested

Journal of Neurology, Neurosurgery and Psychiatry
PsychiatryMental HealthNeurologySurgery
2001English

New Possibilities for the Therapy of Secondary Progressive Multiple Sclerosis

Nevrologiya, Neiropsikhiatriya, Psikhosomatika
PsychiatryClinical PsychologyMental HealthNeurology
2019English

The FLUOX-PMS Trial: Underestimating the Challenge in Progressive Multiple Sclerosis Trials

Multiple Sclerosis
Neurology
2019English

Costs Associated With the Impact of Progressive Multiple Sclerosis: Insights From a Three Year Clinical Trial (The Cupid Trial)

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2013English

Effect of Natalizumab on Disease Progression in Secondary Progressive Multiple Sclerosis (ASCEND): A Phase 3, Randomised, Double-Blind, Placebo-Controlled Trial With an Open-Label Extension

The Lancet Neurology
Neurology
2018English

Motor Evoked Potentials and Disability in Secondary Progressive Multiple Sclerosis

Canadian Journal of Neurological Sciences
MedicineNeurology
1997English

Recommendations From the Expert Meeting «Secondary Progressive Multiple Sclerosis: Unresolved Issues and Prospects»

Nevrologiya, Neiropsikhiatriya, Psikhosomatika
PsychiatryClinical PsychologyMental HealthNeurology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy